Modulation of CD40 expression

摘要

Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40 include hyperproliferative disorders, graft versus host disease (GVHD), graft rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and certain forms of arthritis.

主权项

1. A modified antisense compound 12 to 30 nucleobases in length and having a nucleobase sequence that is at least 90% complementary to an equal length portion of the human CD40 gene but not to other sequences throughout the human genome, selected from the following regions of SEQ ID NO: 4:
(a) positions 11250-12685, corresponding to intron 6; (b) positions 2943-6367, corresponding to intron 1; (c) positions 6447-6780, corresponding to intron 2; (d) positions 6907-7157, corresponding to intron 3; (e) positions 7305-7673, corresponding to intron 4; (f) positions 7768-11187, corresponding to intron 5; (g) positions 12773-12877, corresponding to intron 7; (h) positions 12907-13429, corresponding to intron 8; and (i) positions 13662-16001, which forms part of exon 9 or a region 3′ to exon 9.